Sotrovimab Resistance and Viral Persistence After Treatment of Immunocompromised Patients Infected With the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant

Viral evolution was evaluated in 47 immunocompromised patients treated with sotrovimab. Sequencing of SARS-CoV-2 following therapy was successful in 16. Mutations associated with sotrovimab resistance were documented in 6; viral replication continued after 30 days in 5. Combination antibody therapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Huygens, Sammy, Oude Munnink, Bas, Gharbharan, Arvind, Koopmans, Marion, Rijnders, Bart
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9384506/
https://www.ncbi.nlm.nih.gov/pubmed/35867699
http://dx.doi.org/10.1093/cid/ciac601
_version_ 1784769443213082624
author Huygens, Sammy
Oude Munnink, Bas
Gharbharan, Arvind
Koopmans, Marion
Rijnders, Bart
author_facet Huygens, Sammy
Oude Munnink, Bas
Gharbharan, Arvind
Koopmans, Marion
Rijnders, Bart
author_sort Huygens, Sammy
collection PubMed
description Viral evolution was evaluated in 47 immunocompromised patients treated with sotrovimab. Sequencing of SARS-CoV-2 following therapy was successful in 16. Mutations associated with sotrovimab resistance were documented in 6; viral replication continued after 30 days in 5. Combination antibody therapy may be required to avoid acquired resistance in immunocompromised patients.
format Online
Article
Text
id pubmed-9384506
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-93845062022-08-18 Sotrovimab Resistance and Viral Persistence After Treatment of Immunocompromised Patients Infected With the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant Huygens, Sammy Oude Munnink, Bas Gharbharan, Arvind Koopmans, Marion Rijnders, Bart Clin Infect Dis Brief Report Viral evolution was evaluated in 47 immunocompromised patients treated with sotrovimab. Sequencing of SARS-CoV-2 following therapy was successful in 16. Mutations associated with sotrovimab resistance were documented in 6; viral replication continued after 30 days in 5. Combination antibody therapy may be required to avoid acquired resistance in immunocompromised patients. Oxford University Press 2022-07-22 /pmc/articles/PMC9384506/ /pubmed/35867699 http://dx.doi.org/10.1093/cid/ciac601 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Brief Report
Huygens, Sammy
Oude Munnink, Bas
Gharbharan, Arvind
Koopmans, Marion
Rijnders, Bart
Sotrovimab Resistance and Viral Persistence After Treatment of Immunocompromised Patients Infected With the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant
title Sotrovimab Resistance and Viral Persistence After Treatment of Immunocompromised Patients Infected With the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant
title_full Sotrovimab Resistance and Viral Persistence After Treatment of Immunocompromised Patients Infected With the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant
title_fullStr Sotrovimab Resistance and Viral Persistence After Treatment of Immunocompromised Patients Infected With the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant
title_full_unstemmed Sotrovimab Resistance and Viral Persistence After Treatment of Immunocompromised Patients Infected With the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant
title_short Sotrovimab Resistance and Viral Persistence After Treatment of Immunocompromised Patients Infected With the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant
title_sort sotrovimab resistance and viral persistence after treatment of immunocompromised patients infected with the severe acute respiratory syndrome coronavirus 2 omicron variant
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9384506/
https://www.ncbi.nlm.nih.gov/pubmed/35867699
http://dx.doi.org/10.1093/cid/ciac601
work_keys_str_mv AT huygenssammy sotrovimabresistanceandviralpersistenceaftertreatmentofimmunocompromisedpatientsinfectedwiththesevereacuterespiratorysyndromecoronavirus2omicronvariant
AT oudemunninkbas sotrovimabresistanceandviralpersistenceaftertreatmentofimmunocompromisedpatientsinfectedwiththesevereacuterespiratorysyndromecoronavirus2omicronvariant
AT gharbharanarvind sotrovimabresistanceandviralpersistenceaftertreatmentofimmunocompromisedpatientsinfectedwiththesevereacuterespiratorysyndromecoronavirus2omicronvariant
AT koopmansmarion sotrovimabresistanceandviralpersistenceaftertreatmentofimmunocompromisedpatientsinfectedwiththesevereacuterespiratorysyndromecoronavirus2omicronvariant
AT rijndersbart sotrovimabresistanceandviralpersistenceaftertreatmentofimmunocompromisedpatientsinfectedwiththesevereacuterespiratorysyndromecoronavirus2omicronvariant

Ejemplares similares